For the pharmaceutical industry
Developing targeted therapies comes with the same problem tumor boards face: evidence on biomarkers grows faster than any team can review it. Sphera organises that knowledge in a structured, up-to-date form linked to its sources, and we are open to exploring how it can serve your organisation's objectives.
The Sphera knowledge base structures the relationship between genomic alterations, biomarkers and actionability evidence. That ordered representation makes it easier to analyse which molecular profiles concentrate treatment options, emerging evidence or knowledge gaps relevant to your portfolio.
The same logic that classifies the actionability of a finding can be applied to matching molecular eligibility criteria: which alterations, with what level of evidence, fit a study design. The precise scope of this support is defined project by project, always within the framework agreed by the participating institutions.
Summaries of product characteristics from CIMA, EMA and FDA, reimbursement conditions (BIFIMED), interactions through metabolic pathways such as CYP3A, risk of QT prolongation and toxicity profiles: organised, cross-checked and with every data point referenced to its source document.
As the direct developers of the platform, we can build tailored solutions on the Sphera technological foundation: from specific knowledge modules to integrations with your own systems, within collaboration projects defined jointly.
Every project starts with a conversation about objectives and a scope defined in writing. We work under formal confidentiality agreements and, where the project requires it, alongside the healthcare institutions involved and within their procedures. What we do not do matters as much as what we do: we do not act as an intermediary for patient data, nor do we offer trial recruitment services.
The platform is under development, with the knowledge base consolidated for non-small cell lung cancer (NSCLC). That means early collaborations have a genuine influence on the direction of the product.
Tell us your area of interest — biomarkers, clinical trials, pharmacological knowledge — and we will show you what the platform can do today.
